Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Hashmi, Hamza  [Clear All Filters]
2024
Hashmi H, Kumar A, Kharfan-Dabaja MA, Munshi PN, Inamoto Y, DeFilipp ZM, Dholaria B, Jain T, Perales M-A, Carpenter PA, et al. ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Relapsed Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T-Cell Therapy. Transplant Cell Ther. 2024.
Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldes A, Stölzel F, Rathje K, Fischer L, et al. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2024:JCO2302232.
Gaffney KJ, Bakos JK, Velayati A, Davis JA, Thurlapati A, Weeda E, Maldonado A, Granger K, Butcher C, Herrington T, et al. Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma. J Oncol Pharm Pract. 2024:10781552231224361.
2023
Hashmi H, Shebli A, Jain J, Khasawneh G, Mohan M, Mahmoudjafari Z, Cui W, McGuirk J, Shune L, Ahmed N, et al. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma. Transplant Cell Ther. 2023.
Marini J, Maldonado A, Weeda E, Neppalli A, Hashmi H, Edwards K. Effectiveness, Safety, and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma. Hematol Oncol Stem Cell Ther. 2023;16(4):351-357.
Davis JA, Sborov DW, Wesson W, Julian K, Abdallah A-O, McGuirk JP, Ahmed N, Hashmi H. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther. 2023.
Thurlapati A, Wesson W, Davis JA, Gaffney KJ, Weeda E, Velayati A, Bakos JK, Granger K, Smith D, Maldonado AP, et al. Impact of Cytogenetic Abnormalities, Induction and Maintenance Regimens on Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: A Decade-Long Real-World Experience. J Hematol. 2023;12(6):243-254.
Davis JA, Thurlapati A, Weeda E, Gaffney KJ, Smith D, Maldonado A, Granger K, Martin KE, Williams YM, Herrington T, et al. Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma. Ann Hematol. 2023.
Thurlapati A, McGann M, Davis JA, Granger K, Roubal K, Smith D, Gaffney KJ, Cendagorta A, Herbst A, Hendrickson L, et al. Role of tixagevimab-cilgavimab in preventing SARS-CoV-2 in hematopoietic stem cell transplant and chimeric antigen receptor T-cell therapy recipients. J Med Virol. 2023;95(8):e29027.
Hashmi H, Davis JA, Abdallah A-O. 'A Stitch in Time Saves Nine': Early stem cell transplant continues to improve outcomes in patients with newly diagnosed multiple myeloma. Expert Rev Hematol. 2023.
Hashmi H, Darwin A, Nishihori T. Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed/Refractory Lymphomas. Hematol Oncol Stem Cell Ther. 2023;16(1):21-34.
2022
Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022.
2021
Faizan U, Sana MKhawar, Farooqi MSaad, Hashmi H. Efficacy and Safety of Regimens Used for the Treatment of POEMS Syndrome- A Systematic Review. Clin Lymphoma Myeloma Leuk. 2021.
Hassan H, Anwer F, Javaid A, Hashmi H. Progress in Research: Daratumumab Improves Treatment Outcomes of Patients with AL Amyloidosis. Crit Rev Oncol Hematol. 2021:103435.
Hashmi H, Darwin A, Nishihori T. Therapeutic roles of antibody drug conjugates (ADCs) in relapsed/refractory lymphomas. Hematol Oncol Stem Cell Ther. 2021.
2020
Hashmi H, Bhandari S, Kumar R, Tripathi P, Rhodes JBlancett, Figg L, Baize T, Krem MM, Hegazi M, Emmons R. Twice-daily intravenous bolus tacrolimus infusion: A safe and effective regimen for graft-versus-host disease prophylaxis. Hematol Oncol Stem Cell Ther. 2020.